Watch all of the great on-demand content from our symposium, co-hosted by Biocom California
This symposium brings forth industry experts, who discuss how a significant fraction of the biopharma pipeline is held by small – and even virtual – biopharma companies. These companies often lack all of the capabilities, expertise and/or bandwidth necessary to advance their molecules to initial clinical studies. In the absence of internal resources, small biopharma often look to contract development and manufacturing organizations (CDMOs) to support their development programs. While it is common to support these activities through consultants and multiple CDMOs, studies indicate that working with a single integrated service provider for API and drug product can reduce complexity, development timelines, and costs.